MDT perspectives on novel approaches to overcome resistance with standard-of-care immunotherapy for non-driver mutation metastatic NSCLC

touchMDT for touchONCOLOGY Listen to key experts from a multidisciplinary team review novel approaches to overcome resistance to standard-of-care immunotherapy for non-driver mutation metastatic NSCLC, including new immune checkpoint inhibitor combinations and emerging novel targets. The multidisciplinary team: Oncology Pharmacist: Prof. Lisa Holle, University of Connecticut School of Medicine, Storrs, and UConn Health: Neag Comprehensive Cancer Center, Farmington, CT, USA Medical Oncologist: Prof. Raffaele Califano, The Christie and Manchester University Hospital, Manchester, UK This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/